<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-15T11:23:35+08:00</updated>
  <subtitle>世事洞明皆学问，人情练达即文章</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>ALK抑制剂一线PK，哪个更好？</title>
    <updated>2020-11-15T08:11:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/bAYtouiHMEkwjE2vZ5ErNA</id>
    <link href="https://mp.weixin.qq.com/s/bAYtouiHMEkwjE2vZ5ErNA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Nature重要发现：PD-1抗体“新搭档”——PCSK9抑制剂</title>
    <updated>2020-11-15T08:11:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/Q_zabmF7sR3GOzXIiPvd4A</id>
    <link href="https://mp.weixin.qq.com/s/Q_zabmF7sR3GOzXIiPvd4A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Biotech沉思录</title>
    <updated>2020-11-14T08:16:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-14:/s/fQTyDjHlj4n-oblNqKM2gA</id>
    <link href="https://mp.weixin.qq.com/s/fQTyDjHlj4n-oblNqKM2gA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>KRAS抑制剂「图鉴」</title>
    <updated>2020-11-13T07:37:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/uLS_HBycroJDS7nSHpDwUA</id>
    <link href="https://mp.weixin.qq.com/s/uLS_HBycroJDS7nSHpDwUA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>先声药业战略布局细胞治疗，彰显创新转型决心</title>
    <updated>2020-11-13T07:37:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/29LpuO9zfp0JF-H67rsqIw</id>
    <link href="https://mp.weixin.qq.com/s/29LpuO9zfp0JF-H67rsqIw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首款抗破伤风毒素全人源单抗获批在澳洲进入I期临床</title>
    <updated>2020-11-13T07:37:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/jeC_laf48HQusa5yHiCKEA</id>
    <link href="https://mp.weixin.qq.com/s/jeC_laf48HQusa5yHiCKEA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>荣昌生物维迪西妥单抗获FDA胃癌Ⅱ期临床试验许可及快速通道资格</title>
    <updated>2020-11-13T07:37:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/SAe0fyvAa_HnU2-b0afZ4w</id>
    <link href="https://mp.weixin.qq.com/s/SAe0fyvAa_HnU2-b0afZ4w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>生物分析专栏 | 手性药物的药代动力学和生物分析</title>
    <updated>2020-11-12T07:45:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/LKbevSdAhl4Zxe5rniZVgQ</id>
    <link href="https://mp.weixin.qq.com/s/LKbevSdAhl4Zxe5rniZVgQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>礼来与华西、湘雅达成临床研究战略合作：助力中国临床试验生态系统升级</title>
    <updated>2020-11-12T07:45:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/4_Y4KcvZ8rk_3lwWnq_3wA</id>
    <link href="https://mp.weixin.qq.com/s/4_Y4KcvZ8rk_3lwWnq_3wA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康方生物二代CD47单抗亮相SITC！优势明显，低剂量即实现最大受体占位</title>
    <updated>2020-11-12T07:45:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/lv_p0zvZGll0QXISxaZn0Q</id>
    <link href="https://mp.weixin.qq.com/s/lv_p0zvZGll0QXISxaZn0Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>肺癌研究月报 | 2020年10月</title>
    <updated>2020-11-12T07:45:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/_bBLd6CcFFUTF4Af9ryE8w</id>
    <link href="https://mp.weixin.qq.com/s/_bBLd6CcFFUTF4Af9ryE8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>索元生物首个国际多中心III期临床试验顺利完成受试者入组</title>
    <updated>2020-11-12T07:45:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/_fKj1s_y8QGY5HYGs4PIew</id>
    <link href="https://mp.weixin.qq.com/s/_fKj1s_y8QGY5HYGs4PIew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>瑞科生物完成超1亿美元B轮融资：加速推进9价HPV疫苗、重组新冠疫苗临床开发</title>
    <updated>2020-11-11T07:31:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/GfVCjKssZVzHHvnWzpQGag</id>
    <link href="https://mp.weixin.qq.com/s/GfVCjKssZVzHHvnWzpQGag" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康宁杰瑞HER2双抗联合PD1/CTLA4双抗Ib期研究数据亮相SITC</title>
    <updated>2020-11-11T07:31:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/lDK_zrt_fT8nwaNx6vMr3w</id>
    <link href="https://mp.weixin.qq.com/s/lDK_zrt_fT8nwaNx6vMr3w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>海普瑞原发卵巢癌一线治疗新药Oregovomab再获进展！III期临床试验完成首例患者给药</title>
    <updated>2020-11-11T07:31:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/aVkhaTIfmCYCxmCSKhSwvQ</id>
    <link href="https://mp.weixin.qq.com/s/aVkhaTIfmCYCxmCSKhSwvQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>他山之石，可以攻玉：中国肺癌生存飞跃的“三板斧”</title>
    <updated>2020-11-11T07:31:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/QdCAd3mGdL98MtW1fv5E-g</id>
    <link href="https://mp.weixin.qq.com/s/QdCAd3mGdL98MtW1fv5E-g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>诺奖靶点HIF-2α的新药发现与专利布局</title>
    <updated>2020-11-10T07:39:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/QFV-BzxFtd1m0cCFKy0hyQ</id>
    <link href="https://mp.weixin.qq.com/s/QFV-BzxFtd1m0cCFKy0hyQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>礼来中国总裁季礼文：积极战略转型，聚焦核心领域，加强本土合作</title>
    <updated>2020-11-10T07:39:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/TSBgoYKQ2U0Kb80HYrCjGg</id>
    <link href="https://mp.weixin.qq.com/s/TSBgoYKQ2U0Kb80HYrCjGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>孟鲁司特钠改良新药出现！首个外用凝胶制剂申请临床</title>
    <updated>2020-11-10T07:39:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/bHEkIeFZgXlMG8dBsSLqgg</id>
    <link href="https://mp.weixin.qq.com/s/bHEkIeFZgXlMG8dBsSLqgg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亚盛医药抗耐药白血病新药HQP1351（奥瑞巴替尼）临床进展第三次入选美国血液学会（ASH）年会口头报告</title>
    <updated>2020-11-10T07:39:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/H_LP0C-eYXeIErEyCG3BLA</id>
    <link href="https://mp.weixin.qq.com/s/H_LP0C-eYXeIErEyCG3BLA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>